Cardiac Amyloidosis
ASNC is the premier source for education and quality in the rapidly expanding area of cardiac amyloidosis.
Through its initiatives and partnerships, ASNC is supporting a collaborative approach to awareness, early diagnosis, and effective treatments that will save lives and improve the quality of life for patients with CA. Access the latest educational resources and activities including our guidelines app and share with your colleagues!
NEW ONDEMAND EDUCATION
Learning Objectives
Upon completion of this module, learner will be able to:
- Describe cardiac amyloidosis subtypes and identify symptoms, associated clinical conditions, and typical non-nuclear imaging features.
- Identify appropriate clinical scenarios for the use of Tc99m-PYP/DPD/HMDP imaging in cardiac amyloidosis.
- Apply appropriate Tc99m-PYP/DPD/HMDP, I123-MIBG, and SPECT/PET amyloid binding tracer standardized imaging techniques to optimize assessment of cardiac amyloidosis.
- Interpret and communicate diagnostic and prognostic findings on Tc99m-PYP/DPD/HMDP, I123-MIBG, and SPECT/PET amyloid binding tracers in the assessment of cardiac amyloidosis.
|
Watch Now
|
.png) |
OnDemand: Cardiac Amyloidosis in Latin America: Current Situation and Perspectives
Available for free through July 31, 2024
CARDIAC AMYLOIDOSIS TOOLS
Download these posters and our pocket guide from our Think Amyloid project to distribute to your multidisciplinary care team.
Also available in Spanish.
Cardiac Amyloidosis Flowchart - Exclusive Content for Members!
Access the 11"x17" Cardiac Amyloidosis Flowchart and our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions guide. Not a member? Join ASNC today!
Download our new 11"x17" flowchart designed to guide your clinical assessment of cardiac amyloidosis.
 |
Transthyretin Cardiac Amyloidosis: Frequently Asked Questions Guide - Exclusive Content for Members!
Download our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions guide.
ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging
Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, should not delay imaging in at-risk patients. Instead, ASNC is guiding imagers to use 99mtechnetium (99mTc)-hydroxymethylene diphosphonate (HMDP or HDP) to ensure patients continue receiving prompt evaluation of, and treatment for, cardiac amyloidosis.
|
|
Download the Clinical and Quality Resources App
|
(1).png)
Hover over the QR code with your camera to download
|
ASNC is uniquely qualified to provide education, information and advocacy that ensures appropriate referrals for Tc-99m PYP imaging; supports high-quality testing, interpretation and reporting of Tc-99m PYP imaging by imagers; and encourages fair reimbursement of Tc-99m PYP services and approval of CA treatment agents.